Ozempic cuts risk of death from kidney disease, major study finds

0

The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could dramatically expand the pool of patients eligible for the injections.

Funded by Ozempic maker Novo Nordisk and involving 3,533 patients around the world, a study released in Stockholm at the European Renal Association meeting and published in the New England Journal of Medicine found that patients receiving semaglutide — the key ingredient — experienced a 24 percent reduction in risk of death from cardiovascular and kidney disease compared with those who received a placebo. The finding proved so striking that the company announced in October that it was stopping the trial early, sending shares of some dialysis companies falling then.

FOLLOW US ON GOOGLE NEWS

Source

Leave a comment